Evidence map›Paper›PMID 37432970›Full record

ArticlePloS one2023

Combinatorial targeting of a specific EMT/MET network by macroH2A variants safeguards mesenchymal identity.

Dimitrios Valakos, Eleftheria Klagkou, Antonis Kokkalis, Alexandros Polyzos, Fotis L Kyrilis, Aggelos Banos, Giannis Vatsellas, Maria Pliatska, Ethan Ford, Dimitrios J Stravopodis and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Dimitrios ValakosBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Eleftheria KlagkouBiomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID 0000-0003-3370-607X
Antonis KokkalisBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Alexandros PolyzosBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Fotis L KyrilisBiomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID 0000-0002-4040-6289
Aggelos BanosBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Giannis VatsellasBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Maria PliatskaBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Ethan FordBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Dimitrios J StravopodisSection of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Zografou, Athens, Greece.
Dimitris ThanosBiomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID 0000-0003-4288-3027
Academy of Athens · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generation of induced pluripotent stem cells from specialized cell types provides an excellent model to study how cells maintain their stability, and how they can change identity, especially in the context of disease. Previous studies have shown that chromatin safeguards cell identity by acting as a barrier to reprogramming. We investigated mechanisms by which the histone macroH2A variants inhibit reprogramming and discovered that they work as gate keepers of the mesenchymal cell state by blocking epithelial transition, a step required for reprogramming of mouse fibroblasts. More specifically, we found that individual macroH2A variants regulate the expression of defined sets of genes, whose overall function is to stabilize the mesenchymal gene expression program, thus resisting reprogramming. We identified a novel gene network (MSCN, mesenchymal network) composed of 63 macroH2A-regulated genes related to extracellular matrix, cell membrane, signaling and the transcriptional regulators Id2 and Snai2, all of which function as guardians of the mesenchymal phenotype. ChIP-seq and KD experiments revealed a macroH2A variant-specific combinatorial targeting of the genes reconstructing the MSCN, thus generating robustness in gene expression programs to resist cellular reprogramming.

Indexed as

Cellular ReprogrammingChromatinAnimalsCell MembraneChromatin Immunoprecipitation SequencingExtracellular MatrixMiceChromatin

Identifiers

PMID37432970
PMCPMC10335705
OpenAlexW4383874999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.